May 15, 2023
3 min watch
Save
VIDEO: Machine learning could identify relapse risk for renal cell carcinoma
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
In this video, Brad McGregor, MD, discussed data regarding adjuvant therapies for renal cell carcinoma presented at the American Urological Association Annual Meeting.
McGregor, clinical director of Dana-Farber Cancer Institute’s Lank Center for Genitourinary Cancer, highlighted a study from the French UroCCR network that used machine learning to develop an algorithm that could identify patients who had the largest risk for relapse.
“It’s early data overall, but it’s novel approaches like this that are going to be necessary to find who is going to be at risk for relapse, and where we can really improve therapy in that adjuvant setting,” McGregor said.
Published by:
Sources/Disclosures
Collapse
Disclosures:
McGregor reports consulting for Astellas, BMS, Exelixis, Eisai, Pfizer and SeaGen, and receiving research funding to his institution from BMS, Exelixis, Gilead and SeaGen.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.